IMMX

Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relaps

Immix Biopharma reported an 89% complete-response rate in an interim update covering all NEXICART-2 patients. The MRD-negative results create a near-term clinical catalyst around whether the therapy can sustain its potential efficacy in relapsed disease.